Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul;53(1):55-9.
doi: 10.3164/jcbn.12-116. Epub 2013 Apr 9.

Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injury

Affiliations

Nonsteroidal anti-inflammatory drug-induced visible and invisible small intestinal injury

Yoshitsugi Ito et al. J Clin Biochem Nutr. 2013 Jul.

Abstract

Permeation of the small intestinal mucosa is a key mechanism in the induction of enteropathy. We investigated the effect of rebamipide in healthy subjects with diclofenac-induced small intestinal damage and permeability. In this crossover study, each treatment period was 1 week with a 4-week washout period. Diclofenac (75 mg/day) and omeprazole (20 mg/day) plus rebamipide (300 mg/day) or placebo were administered. Capsule endoscopy and a sugar permeability test were performed on days 1 and 7 in each period. Ten healthy subjects were enrolled. Small intestinal injuries were observed on day 7 in 6 of 10 subjects in both groups. Urinary excretion of administered lactulose increased from 0.30% to 0.50% of the initial dose during the first treatment period in the placebo group, and from 0.13% to 0.33% in the rebamipide group. Despite recovery from small-intestinal mucosal damage, the increased permeability in both groups resulted in sustained high levels of lactulose (0.50% to 1.06% in the placebo group and 0.33% to 1.12% in the rebamipide group) through the 4-week washout period. Diclofenac administration induced enteropathy and hyperpermeability of the small intestine. The sustained hyperpermeability during the washout period may indicate the presence of invisible fragility.

Keywords: diclofenac; healthy subjects; permeability; rebamipide; small intestinal damage.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study protocol —Crossover design—.
Fig. 2
Fig. 2
Changes in sugar excretion. Permeability was described as percent of the initial dose according to the following formula: excretion of sugar in urine (mg/ml) × urine volume (ml)/quantity of sugar loading (mg) × 100. Changes in excretion of sugars were defined as differences between the baseline and day 7 levels.
Fig. 3
Fig. 3
Time course of lactulose excretion in urine. Closed circles represent the placebo group, and open circles represent the rebamipide group. Diclofenac use is associated with a linear increase of lactulose urinary excretion level during the washout period despite the recovery from small intestinal injury.

Similar articles

Cited by

References

    1. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;4:CD002296. - PubMed
    1. Iddan G, Meron G, Glukhovsky, et al. Wireless capsule endoscopy. Nature. 2000;405:417. - PubMed
    1. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55–59. - PubMed
    1. Bjarnason I, Hayllar J, Smethurst P, Price A, Gumpel MJ. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut. 1992;33:1204–1208. - PMC - PubMed
    1. Watanabe T, Tanigawa T, Nadatani Y, et al. Mitochondrial disorders in NSAIDs-induced small bowel injury. J Clin Biochem Nutr. 2011;48:117–121. - PMC - PubMed